Neonatal outcomes following new reimbursement limitations on palivizumab in Italy

OBJECTIVE: To evaluate the impact of new reimbursement decisions for palivizumab treatment on respiratory syncytial virus (RSV) hospitalisations and the concomitant number of palivizumab prescriptions for infants aged <2 years. DESIGN: We compared the RSV hospitalisation rates in infants before a...

Descripción completa

Detalles Bibliográficos
Autores principales: Belleudi, Valeria, Trotta, Francesco, Pinnarelli, Luigi, Davoli, Marina, Addis, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Drug Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287565/
https://www.ncbi.nlm.nih.gov/pubmed/30217858
http://dx.doi.org/10.1136/archdischild-2018-315349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287565/
https://www.ncbi.nlm.nih.gov/pubmed/30217858
http://dx.doi.org/10.1136/archdischild-2018-315349

Ejemplares similares